Posted by Michael Wonder on 31 Mar 2026
ICER publishes final evidence report on therapies for IgA nephropathy
31 March 2026 - Independent appraisal committee found a net health benefit for sibeprenlimab, atacicept, and Nefecon.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of sibeprenlimab (Voyxact, Otsuka), atacicept (Vera Therapeutics), and delayed release budesonide (“Nefecon”, Tarpeyo, Calliditas Therapeutics) for IgA nephropathy.
